RxDoctor Payments Data

Seema Haque, MD

Psychiatry · Arlington, TXNPI 1396784914

Payments from drug & device makers

$5,985in general payments, 2019–2025

Across 298 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alkermes, Inc.$693
  • Johnson & Johnson$542
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$482
  • Otsuka America Pharmaceutical, Inc.$480
  • Takeda Pharmaceuticals U.S.A., Inc.$350
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,93699%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,985 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$47,495
Medicare patients
118
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole23$31,317
FanaptIloperidone12$20,115
Lurasidone Hcl35$11,829
Aripiprazole206$9,726
Duloxetine Hcl416$6,173
Buspirone Hcl273$4,259
Ziprasidone Hcl72$4,033
Venlafaxine Hcl ErVenlafaxine Hcl196$3,536
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$2,987
Quetiapine Fumarate261$2,726
Doxepin Hcl112$2,719
Paroxetine Hcl210$2,545
Bupropion XlBupropion Hcl120$2,282
Olanzapine124$2,227
Asenapine Maleate11$2,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$480$31,31723 claims
Vanda Pharmaceuticals Inc.Fanapt$115$20,11512 claims
Almatica Pharma LLCSertraline Hcl$112$669105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →